EUVIMEDEUVIMED entdecken
Crossref

A High‐Nuclear Silver Cluster Incorporated Polyoxoniobate Boosts Antitumor Immunity With Low Systemic Toxicity

Qian-Sheng Lai iD, Yan-Ling Chen, Xin-Xiong Li iD, Peng Xu iD, Shou-Tian Zheng iD

Angewandte Chemie International Edition · 29.10.2026

DOI: 10.1002/anie.6973638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 29.10.2026. Verfasst von Qian-Sheng Lai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory of Advanced Inorganic Oxygenated Materials, College of Chemistry, Fuzhou University, Fuzhou, Fujian, China. Die Arbeit nennt 74 Literaturangaben. Gefördert von: Natural Science Foundation of China, Fujian Provincial Department of Science and Technology, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy is limited by insufficient immunomodulatory efficacy and systemic toxicity. This study reports a giant silver cluster‐incorporated polyoxoniobate (PONb), K 6 Na 21 H 39 {Ag 30 Cl 4 (SeO 3 ) 4 @(SiNb 18 O 54 ) 6 }·96H 2 O ( 1 ), as a potent immunotherapeutic agent. 1 features a unique core‐shell architecture, comprising a silver cluster core [Ag 30 Cl 4 (SeO 3 ) 4 ] 18+ and a shell of six [SiNb 18 O 54 ] 14− polyanions. Notably, 1 contains the largest silver cluster (30 Ag + ) in a molecular PONb with solubility and biocompatibility under physiological conditions to date. In vitro, 1 exhibits potent cytotoxicity against mouse colorectal carcinoma cells with an IC 50 of 0.11 µM, triggering immunogenic cell death (ICD). Additionally, it induces polarization of macrophages to the antitumor M1‐phenotype. In vivo, it outperforms doxorubicin (DOX) in suppressing tumor growth, with 1 achieving 90.63% tumor inhibition at 5 mg/kg (0.23 µmol/kg). Unlike DOX‐induced immunosuppression and hepatic toxicity, 1 robustly activates antitumor immune response via an ROS‐dependent mechanism by promoting T cell priming in the tumor‐draining lymph node and effector T cell infiltration into tumors, without impairing organ functions. Moreover, 1 converts tumor‐associated macrophages (TAMs) from the protumorogenic M2‐phenotype to the antitumor M1‐phenotype, further reprogramming the immune microenvironment in tumor tissues. This study validates PONbs as a promising class of immunotherapeutics, bridging structural innovation in inorganic chemistry with improved cancer immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

antitumorimmunotherapypolyoxometalatepolyoxoniobatesilver cluster

Autor:innen und Institutionen

  • Fujian Provincial Key Laboratory of Advanced Inorganic Oxygenated Materials, College of Chemistry, Fuzhou University, Fuzhou, Fujian, China.
  • College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, China.

ORCID-Profile: Qian-Sheng Lai, Xin-Xiong Li, Peng Xu, Shou-Tian Zheng

Förderung

  • Natural Science Foundation of China
  • Fujian Provincial Department of Science and Technology
  • National Natural Science Foundation of China

Zitieren

APA

Lai, Q. S., Chen, Y. L., Li, X. X., Xu, P., & Zheng, S. T. (2026). A High‐Nuclear Silver Cluster Incorporated Polyoxoniobate Boosts Antitumor Immunity With Low Systemic Toxicity. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.6973638

Vancouver

Lai QS, Chen YL, Li XX, Xu P, Zheng ST. A High‐Nuclear Silver Cluster Incorporated Polyoxoniobate Boosts Antitumor Immunity With Low Systemic Toxicity. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.6973638

BibTeX
@article{Lai2026,
  author = {Lai, Qian-Sheng and Chen, Yan-Ling and Li, Xin-Xiong and Xu, Peng and Zheng, Shou-Tian},
  title = {A High‐Nuclear Silver Cluster Incorporated Polyoxoniobate Boosts Antitumor Immunity With Low Systemic Toxicity},
  journal = {Angewandte Chemie International Edition},
  year = {2026},
  doi = {10.1002/anie.6973638}
}
Kostenlos starten →